Abstract
When antipsychotics were introduced into clinical psychiatry in the 1950’s extrapyramidal motor side effects (EPS) were felt to be an integral part of their profile of action. The propensity to induce EPS in animal models was an important part of the screening procedures in the development of antipsychotics. The term “neuroleptic” that was coined to characterize this new class of drugs had to do with their impact on motor functions. It wasn’t until the development of clozapine that psychopharmacologists realized that antipsychotic efficacy is not necessarily linked to EPS.
This paper is dedicated to the memory of Theodore van Putten, M.D.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bishop MP, Gallant DM, Sykes TF (1965) Extrapyramidal side effects and therapeutic response. Arch Gen Psychiatry 13:155–162.
Buchanan RW, Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter Jr WT (1992) Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry 32:72–78.
Chakos MH, Mayerhoff DI, Loebel AD, Alvier JM, Lieberman JA (1992) Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 28:81–86.
Cohen BM, Keck PE, Satlin A, Cole JO (1991) Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 29:1215–1219.
Fleischhacker WW, Meise U, Günther V, Kurz M (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 89[Suppl 382]: 11–15.
Goldman D (1961) Parkinsonism and related phenomena from administration of drugs: their production and control under clinical conditions and possible relation to therapeutic effect. Rev Can Biol 20:549–560.
Hogan TP, Awad AG (1992) Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22:347–352.
Hollister LE, Chaffey EM, Klett CJ (1960) Abnormal symptoms, signs and laboratory tests during treatment with phenothiazine derivatives. Clin Pharmacol Ther 1:284–293.
Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephanos J, Silver P (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47:761–768.
Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J (1987) Prediction of relapse in schizophrenia. Arch Gen Psychiatry 44:597–603.
McEvoy JP, Schooler NR, Wilson WH (1991) Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol Bull 27:97–101.
McEvoy JP, Hogarty GE, Steingard S (1991a) Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 48:739–745.
Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67–72.
Van Putten T, May PRA, Marder SR (1984) Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41:1036–1039.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Wien
About this paper
Cite this paper
Fleischhacker, W.W. (1994). Extrapyramidal side-effects and prediction of neuroleptic treatment response. In: Gaebel, W., Awad, A.G. (eds) Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6636-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6636-9_9
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82602-7
Online ISBN: 978-3-7091-6636-9
eBook Packages: Springer Book Archive